Investigating the synergistic efficacy of BMP-7 and zoledronate on bone allografts using an open rat osteotomy model

Bone

Volumn 56, Issue 2, 2013, Pages 440-448

  Mathavan, Neashan ^a   Bosemark, Per ^a   Isaksson, Hanna ^a,b   Tägil, Magnus ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Anabolism; Bisphosphonate; Bone morphogenetic protein (BMP); Catabolism; Fracture healing

Indexed keywords

RECOMBINANT OSTEOGENIC PROTEIN 1; SODIUM CHLORIDE; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ALLOGRAFT; BONE MASS; BONE RADIOGRAPHY; CALLUS; CATABOLISM; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL MODEL; FEMUR FRACTURE; FEMUR OSTEOTOMY; FRACTURE HEALING; FRACTURE NONUNION; FROZEN SECTION; HISTOPATHOLOGY; KIRSCHNER WIRE; MALE; MECHANICAL STIMULATION; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; RADIOGRAPHY DEVICE; RAT; SINGLE DRUG DOSE; TIBIA; WIRE FIXATION;

ANABOLISM; BISPHOSPHONATE; BONE MORPHOGENETIC PROTEIN (BMP); CATABOLISM; FRACTURE HEALING;

ALLOGRAFTS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEIN 7; BONE TRANSPLANTATION; DIPHOSPHONATES; FEMUR; FRACTURE HEALING; IMIDAZOLES; MALE; OSTEOTOMY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84882663410     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.06.030     Document Type: Article

References (56)

1. Einhorn T.A. Enhancements of fracture-healing. J Bone Joint Surg 1995, 77-A(6):940-956.
2. Little D.G., Ramachandran M., Schindeler A. The anabolic and catabolic responses in bone repair. J Bone Joint Surg Br 2007, 89-B(4):425-433.
3. Webb J.C.J., Tricker J. A review of fracture healing 2000, 14(6):457-463.
4. Sibai T., Morgan E., Einhorn T. Anabolic agents and bone quality. Clin Orthop Relat Res 2011, 469(8):2215-2224.
5. Giannoudis P.V., Dinopoulos H., Tsiridis E. Bone substitutes: an update. Injury 2005, 36(3, Supplement):S20-S27.
6. Dinopoulos H., Dimitriou R., Giannoudis P.V. Bone graft substitutes: what are the options?. Surgeon 2012, 10(4):230-239.
7. De Long W.G., Einhorn T.A., Koval K., McKee M., Smith W., Sanders R., et al. Bone grafts and bone graft substitutes in orthopaedic trauma surgery: a critical analysis. J Bone Joint Surg 2007, 89(3):649-658.
8. Finkemeier C.G. Bone-grafting and bone-graft substitutes. J Bone Joint Surg 2002, 84(3):454-464.
9. Arrington E.D., Smith W.J., Chambers H.G., Bucknell A.L., Davino N.A. Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res 1996, 329:300-309.
10. Keating J.F., McQueen M.M. Substitutes for autologous bone graft in orthopaedic trauma. J Bone Joint Surg Br 2001, 83(1):3-8.
11. Palmer S.H., Gibbons C.L.M.H., Athanasou N.A. The pathology of bone allograft. J Bone Joint Surg Br 1999, 81-B(2):333-335.
12. Sandhu H.S., Grewal H.S., Parvataneni H. Bone grafting for spinal fusion. Orthop Clin North Am 1999, 30(4):685-698.
13. Termaat M.F., Den Boer F.C., Bakker F.C., Patka P., Haarman H.J.Th.M. Bone morphogenetic proteins - development and clinical efficacy in the treatment of fractures and bone defects. J Bone Joint Surg 2005, 87(6):1367-1378.
14. Hogan B.L. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 1996, 10(13):1580-1594.
15. Urist M.R. Bone morphogenetic protein: the molecularization of skeletal system development. J Bone Miner Res 1997, 12(3):343-346.
16. Urist M.R. Bone: formation by autoinduction. Science 1965, 150(3698):893-899.
17. Gautschi O.P., Frey S.P., Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J Surg 2007, 77(8):626-631.
18. Giannoudis P., Kanakaris N., Einhorn T. Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: review of the existing evidence. Osteoporos Int 2007, 18(12):1565-1581.
19. Cheng H., Jiang W., Phillips F.M., Haydon R.C., Peng Y., Zhou L., et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg 2003, 85(8):1544-1552.
20. Udagawa N. Mechanisms involved in bone resorption. Biogerontology 2002, 3(1-2):79-83.
21. Itoh K., Udagawa N., Katagiri T., Iemura S., Ueno N., Yasuda H., et al. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-κB ligand. Endocrinology 2001, 142(8):3656-3662.
22. Katagiri T., Takahashi N. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 2002, 8(3):147-159.
23. Little D.G., McDonald M., Bransford R., Godfrey C.B., Amanat N. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res 2005, 20(11):2044-2052.
24. Kanatani M., Sugimoto T., Kaji H., Kobayashi T., Nishiyama K., Fukase M., et al. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J Bone Miner Res 1995, 10(11):1681-1690.
25. Kaneko H., Arakawa T., Mano H., Kaneda T., Ogasawara A., Nakagawa M., et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 2000, 27(4):479-486.
26. Russell R.G.G. Bisphosphonates: the first 40years. Bone 2011, 49(1):2-19.
27. Eastell R., Walsh J.S., Watts N.B., Siris E. Bisphosphonates for postmenopausal osteoporosis. Bone 2011, 49(1):82-88.
28. Harding A.K., Aspenberg P., Kataoka M., Bylski D., Tägil M. Manipulating the anabolic and catabolic response in bone graft remodeling: synergism by a combination of local BMP-7 and a single systemic dose of zoledronate. J Orthop Res 2008, 26(9):1245-1249.
29. Jeppsson C., Åstrand J., Tägil M., Aspenberg P. A combination of bisphosphonate and BMP additives in impacted bone allografts. Acta Orthop 2003, 74(4):483-489.
30. McDonald M.M., Schindeler A., Little D.G. Bisphosphonate treatment and fracture repair. IBMS BoneKEy 2007, 4(9):236-251.
31. Yu N.Y.C., Schindeler A., Tägil M., Ruys A.J., Little D.G. Use of BMPs and bisphosphonates to improve bone fracture healing. Front Biosci 2012, E4:2647-2653.
32. Kozloff K.M., Volakis L.I., Marini J.C., Caird M.S. Near-infrared fluorescent probe traces bisphosphonate delivery and retention in vivo. J Bone Miner Res 2010, 25(8):1748-1758.
33. Rogers M.J., Crockett J.C., Coxon F.P., Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011, 49(1):34-41.
34. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38(5):617-627.
35. Schindeler A., Little D.G. Bisphosphonate action: revelations and deceptions from in vitro studies. J Pharm Sci 2007, 96(8):1872-1878.
36. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356(18):1809-1822.
37. Doi Y., Miyazaki M., Yoshiiwa T., Hara K., Kataoka M., Tsumura H. Manipulation of the anabolic and catabolic responses with BMP-2 and zoledronic acid in a rat femoral fracture model. Bone 2011, 49(4):777-782.
38. Einhorn T. Can an anti-fracture agent heal fractures?. Clin Cases Miner Bone Metab 2010, 7(1):11-14.
39. Gerstenfeld L.C., Sacks D.J., Pelis M., Mason Z.D., Graves D.T., Barrero M., et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009, 24(2):196-208.
40. Bosemark P., Isaksson H., McDonald M.M., Little D.G., Tägil M. Augmentation of autologous bone graft by a combination of bone morphogenic protein and bisphosphonate increased both callus volume and strength. Acta Orthop 2013, 84(1):106-111.
41. Belfrage O., Flivik G., Sundberg M., Kesteris U., Tägil M. Local treatment of cancellous bone grafts with BMP-7 and zoledronate increases both the bone formation rate and bone density. Acta Orthop 2011, 82(2):228-233.
42. Tägil M., McDonald M.M., Morse A., Peacock L., Mikulec K., Amanat N., et al. Intermittent PTH(1-34) does not increase union rates in open rat femoral fractures and exhibits attenuated anabolic effects compared to closed fractures. Bone 2010, 46(3):852-859.
43. Bonnarens F., Einhorn T.A. Production of a standard closed fracture in laboratory animal bone. J Orthop Res 1984, 2(1):97-101.
44. Chen X., Kidder L.S., Lew W.D. Osteogenic protein-1 induced bone formation in an infected segmental defect in the rat femur. J Orthop Res 2002, 20(1):142-150.
45. Morgan E.F., Mason Z.D., Chien K.B., Pfeiffer A.J., Barnes G.L., Einhorn T.A., et al. Micro-computed tomography assessment of fracture healing: relationships among callus structure, composition, and mechanical function. Bone 2009, 44(2):335-344.
46. McDonald M.M., Dulai S., Godfrey C., Amanat N., Sztynda T., Little D.G. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone 2008, 43(4):653-662.
47. Wilkinson J.M., Little D.G. Bisphosphonates in orthopedic applications. Bone 2011, 49(1):95-102.
48. Amanat N., Brown R., Bilston L.E., Little D.G. A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res 2005, 23(5):1029-1034.
49. Iwata K., Li J., Follet H., Phipps R.J., Burr D.B. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 2006, 39(5):1053-1058.
50. Nakamura M., Udagawa N., Matsuura S., Mogi M., Nakamura H., Horiuchi H., et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 2003, 144(12):5441-5449.
51. Bikle D.D., Morey-Holton E.R., Doty S.B., Currier P.A., Tanner S.J., Halloran B.P., et al. Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage. J Bone Miner Res 1994, 9(11):1777-1787.
52. Reinholz G.G., Getz B., Pederson L., Sanders E.S., Subramaniam M., Ingle J.N., et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000, 60(21):6001-6007.
53. Reinholz GG, Getz B, Sanders ES, Karpeisky MY, Padyukova NS, Mikhailov SN, et al.Distinct mechanisms of bisphosphonate action between osteoblasts and breastcancer cells: identity of a potent new bisphosphonate analogue. Breast CancerRes Treat 2002;71(3):257-68.
54. Allen MR, Burr DB. Bisphosphonate effects on bone turnover, microdamage, andmechanical properties: what we think we know and what we know that wedon't know. Bone 2011;49(1):56-65.
55. Agholme F, Aspenberg P. Experimental results of combining bisphosphonateswith allograft in a rat model. J Bone Joint Surg Br 2009;91-B(5):670-5.
56. Amanat N, McDonald M, Godfrey C, Bilston L, Little DG. Optimal timing of a singledose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res2007;22(6):867-76.